Social determinants and structural inequities such as systemic racism, segregation, discriminatory policies, socioeconomic status, education, neighborhoods and physical environments, employment, social support structures, and access to healthcare largely drive asthma disparities.Ī recent review has highlighted that warming winters are likely to result in an expanded range for some tropical plants and animals across the United States. The Asthma and Allergy Foundation of America reported that asthma disproportionately affects Black, Hispanic, and native populations, who all have higher asthma rates, hospitalizations, and death. pollen season from 11 to 27 days, a trend that will only increase the length and severity of seasonal allergies. From 1995 to 2011, warmer temperatures have increased the U.S. Roughly 7.8% of Americans who are 18 and older have hay fever and 7.7% of adults have asthma. These higher concentrations of pollen exacerbate allergies and asthma. As temperatures warm, flowers and plants bloom earlier which increases the concentration of pollen and carbon dioxide. Institute of Infectious Disease and Molecular Medicineįaculty of Health Sciences, University of Cape Townĭr Klaus Pors, University of Bradford, UK, Recombinant antibody drug conjugatesĭr Mehmet K.Asthma and seasonal allergies will become worse as temperatures increase from climate change according to the Asthma and Allergy Foundation of America. See publications and profile on Research Gate.ĭepartment of Integrative Biomedical Sciences Novel fusion proteins will be designed using advanced supercomputing tools to model dynamic interactions of proteins, in close collaboration with Prof Dr Paolo Carloni, Institute for Advanced Simulation, Forschungszentrum Jülich, Germany. Recombinant fusion proteins are mainly expressed in bacterial or mammalian cells and subsequently characterised in experimental settings, both in vitro on cell lines or primary material of patients and in vivo in transgenic/tumor-bearing mouse models.
Tur, Experimental Pathology and Immunotherapy, Institute for Pathology, University Hospital Giessen and Marburg, Germany, andī) Dr Peter Duncan, Afrobodies, South Africa. Novel methods for selection of antibodies are developed in close collaboration with:Ī) Dr Mehmet K.
The main characteristics of these novel agents are: The major aim of our research is the use of medical biotechnology methods including antibody technologies, protein engineering and expression, to develop and evaluate knowledge-based innovative recombinant immunodiagnostics and therapeutics. Tier 1 South African Research Chair in Cancer Biotechnology Division of Chemical & Systems Biology Department of Integrative Biomedical Sciences Member Member and Executive Director, Medical Biotechnology and Immunotherapy Unit Faculty of Health Sciences. Selected publications | Contact details | Group members | Collaborations
0 kommentar(er)
